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ABSTRACT Piperacillin-tazobactam (P/T) is a -lactam–-lactamase inhibitor combina-
tion frequently used in the hospital setting. Etest is a gradient diffusion method that
represents an alternative to broth microdilution (BMD) for performing antimicrobial sus-
ceptibility testing. We conducted a multicenter evaluation of the performance of the
new P/T Etest compared to that of BMD following U.S. Food and Drug Administration
(FDA) and International Standards Organization (ISO) standard ISO 20776-2 criteria using
Clinical and Laboratory Standards Institute (CLSI)-FDA and European Committee on Anti-
microbial Susceptibility Testing (EUCAST) interpretive breakpoints, respectively. A total of
977 isolates (775 Enterobacterales isolates, 119 Pseudomonas aeruginosa isolates, and 83
Acinetobacter baumannii complex isolates) were tested. Overall essential agreement (EA)
was 96.4% and 96.6% for Enterobacterales when FDA and ISO 20776-2 criteria, respec-
tively, were followed. EA was 98.3% for P. aeruginosa and 91.6% for the A. baumannii
complex when both the FDA and ISO criteria were followed. Applying CLSI-FDA break-
points, categorical agreement (CA) reached 93.0%, 93.3%, and 89.2% for the Enterobacte-
rales, P. aeruginosa, and the A. baumannii complex, respectively. Two very major errors
(VMEs; 1.1%) were found among the Enterobacterales (for 2 Klebsiella pneumoniae iso-
lates). No additional major errors (MEs) or VMEs were found. Applying EUCAST breakpoints,
CA was 94.8% and 95.8% for Enterobacterales and P. aeruginosa, respectively (no breakpoints
are currently available for the A. baumannii complex). No VMEs were observed among the
Enterobacterales, but 2 (0.4%) MEs were found. Among the P. aeruginosa isolates, 2 (6.9%)
VMEs and 3 (3.3%) MEs were observed. These errors resulted when P/T Etest MICs were 1
doubling dilution apart from the BMD MICs. In conclusion, the new P/T Etest represents an
accurate tool for performing antimicrobial susceptibility testing of Enterobacterales, P. aerugi-
nosa, and A. baumannii complex isolates with limited category errors.
KEYWORDS piperacillin-tazobactam, Etest, antimicrobial susceptibility testing,
gradient diffusion, Enterobacterales, Pseudomonas aeruginosa, Acinetobacter
baumannii complex
Piperacillin-tazobactam (P/T) is a -lactam–-lactamase inhibitor combination fre-quently used in the routine clinical setting. Piperacillin is a semisynthetic ureido-
penicillin that has activity against both Gram-negative and Gram-positive bacteria but
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that has a reduced efficacy in the presence of different -lactamases. Tazobactam, a
penicillanic acid -lactamase inhibitor, protects the activity of piperacillin against
Gram-negative isolates producing narrow-spectrum or some extended-spectrum
-lactamases (ESBL) (1–3). Due to the worldwide dispersion of ESBL producers,
piperacillin-tazobactam has been viewed as a carbapenem-sparing option (4–6), al-
though controversial reports have also been reported (7, 8).
Although broth microdilution (BMD) is the gold standard method to perform
antimicrobial susceptibility testing (9), it is rarely performed in most clinical settings as
it is labor-intensive and time-consuming and requires specialized expertise. In addition,
several commercial automated susceptibility testing systems as well as disk diffusion
are used in routine clinical microbiology laboratories. Easy-to-perform, ancillary tests
may also be used to obtain MIC values. Among those, gradient diffusion methods were
developed for different antimicrobials, including piperacillin-tazobactam (10). However,
in 2015 the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
published a warning about problems with piperacillin-tazobactam gradient tests, in-
cluding Etest PTc (bioMérieux, France). The results of that test were reported to be
unreliable due to high variations in MIC values with high category error rates (http://
www.eucast.org/ast_of_bacteria/warnings/). Concomitantly, the Etest PTc strip was
withdrawn from the market.
We report here the results of an international multicenter evaluation of the recently
redesigned piperacillin-tazobactam gradient diffusion strip (P/T Etest; bioMérieux,
Marcy l’Etoile, France), approved by the European Union (CE marked in December 2018)
and the U.S. Food and Drug Administration (FDA) (January 2019). The aim was to test
the equivalence of its performance to that of the reference BMD method to determine
the antimicrobial susceptibilities of Enterobacterales, Pseudomonas aeruginosa, and
Acinetobacter baumannii complex isolates.
MATERIALS AND METHODS
Ethics statement. Prior to study initiation, each study site acquired approval or a waiver from the
respective institutional review board.
Study setting and design. The performance of the P/T Etest was compared to that of the broth
microdilution (BMD) reference method following Clinical and Laboratory Standards Institute (CLSI)
M07-A10 (11) and International Standards Organization (ISO) ISO 20776-1 (9) standards. The study design
included four performance components: (i) a challenge study, (ii) a clinical study, (iii) a quality control
(QC) study, and (iv) a reproducibility study. Inoculum purity was verified for all isolates tested, regardless
of the study component. Inoculum density was checked for all quality control replicates, all reproduc-
ibility tests, and 10% of the fresh clinical isolates following FDA guidance (12).
The study was conducted between June and October 2018 at 4 different sites, including 3 sites in the
United States and 1 site in Europe. The roles of the different sites were as follows: the University Hospital
Ramón y Cajal, Madrid, Spain (HRC), performed a clinical study and a quality control study; the University
of Rochester Medical Center, Rochester, NY, USA (Rochester), performed a clinical study, quality control
study, and reproducibility study; the Washington University in Saint Louis School of Medicine, Saint Louis,
MO, USA (WashU), performed a clinical study, quality control study, and reproducibility study; and the
Clinical Affairs Laboratory, Saint Louis bioMérieux, Saint Louis, MO, USA (STL), performed a challenge
study, clinical study, quality control study, and reproducibility study.
Challenge and clinical studies. The challenge set was composed of 89 stock isolates. Between June
and October 2018, the clinical study recruited 888 clinical isolates, including 448 (50.5%) fresh isolates
(isolates tested by up to 7 days from the time isolation and never frozen), 278 (31.3%) recent isolates
(isolates tested between 7 days and 1 year from the time of isolation and stored frozen), and 162
(18.2%) stock isolates (isolates tested from 1 to 3 years from the time of isolation). Isolates were
identified using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrom-
etry according to each site’s internal procedures. No duplicate isolates from the same patient were
included. A single 0.5 McFarland standard suspension of each isolate was used to perform the P/T Etest
and BMD.
For the P/T Etest, Mueller-Hinton agar plates (BD, Franklin Lakes, NJ, USA) were inoculated by use of
a sterile cotton swab moistened with the 0.5 McFarland standard suspension, and the P/T Etest strip was
placed on the plate with an applicator or forceps. The P/T Etest result was read according to the
manufacturer’s instructions, also included in the package insert, after 16 to 20 h of incubation at 35  2°C
(20 to 24 h for A. baumannii). The MIC was read at the location of the complete inhibition of growth. An
MIC falling between 2 standard doubling dilutions was rounded up to the next highest value before
categorization (Fig. 1). Haze and macrocolonies or microcolonies within 3 mm from the strip were read
as growth (Fig. 1).
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BMD was performed in frozen 96-well plates prepared in bioMérieux facilities (La Balme les Grottes,
France) in compliance with the directions for the CLSI M07-A10 (11) and ISO 20776-1 (9) standards. Each
batch produced was controlled by inoculating several panels withdrawn at the beginning, at the middle,
and at the end of production with the QC strains recommended by the CLSI M100 standard (13). The
panels were then frozen at 80°C and shipped in dry ice with constant monitoring of the temperature
during transportation at all clinical trial sites. The P/T MIC range tested was 0.016 to 256 mg/liter.
Performance was expressed by the use of the data from the clinical and challenge studies combined.
MIC values were interpreted using both CLSI and EUCAST breakpoints (13, 14, 15) (Table 1). Performance
was expressed using the following indices: essential agreement (EA), categorical agreement (CA), minor
error (mE) rate, major error (ME) rate, and very major error (VME) rate. These indices were then compared
to the performance criteria defined by the FDA (12) and ISO 20776-2 (16) standards. The performances
obtained using EUCAST breakpoints are presented after resolution of the VMEs according to section 5.7.2
of the ISO 20776-2 standard (16). Briefly, for EUCAST-ISO analysis, resolution of MEs and VMEs was
attempted by a triplicate test of the reference method only. The consensual BMD mode/median result
replaced the initial BMD result. If no consensus result emerged from the triplicate BMD, the isolate was
excluded from the analysis. For CLSI-FDA analysis, no resolution of discrepant results was performed.
Reproducibility study. Twelve isolates were included in the reproducibility study, and testing was
performed at three sites. Each isolate was tested in triplicate each day on three different days. Three
separate 0.5 McFarland standard suspensions of each isolate were prepared in normal sterile saline on
each day of reproducibility testing. Each suspension was used for the P/T Etest procedure. The results of
the testing were used to compute a modal value for each reproducibility study isolate (if there was no
mode, the median was used). Results that were within 1 doubling dilution of the mode were within
agreement and were used to calculate the percentage of isolates for which the results were within
agreement. Best-case calculation for reproducibility assumed that the off-scale values were within 1
doubling dilution of the mode. Worst-case calculation assumed that off-scale values were not within 1
doubling dilution of the mode. Reproducibility was calculated as the ratio between the number of results
with essential agreement over the total number of results. Both within- and between-site reproducibi-
lities are expressed as percentages.
Quality control. Tests with the quality control isolates for the P/T Etest and BMD methods were
conducted at each study site on each day of testing using the following organisms: Escherichia coli ATCC
25922, E. coli ATCC 35218, Klebsiella pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, Enterococcus
FIG 1 Characteristic ellipses observed with QC strains and examples of the results obtained with clinical isolates and the related MICs. (A) QC strain E. coli ATCC
25922 (MIC  2 g/ml); (B) QC strain P. aeruginosa ATCC 27853 (MIC  3 g/ml); (C) K. pneumoniae clinical isolate (MIC  3 g/ml) with a pear-shaped ellipse;
(D) K. pneumoniae clinical isolate (MIC  128 g/ml) displaying macrocolonies.
TABLE 1 Piperacillin-tazobactam breakpointsa
Organism
CLSI breakpoint (mg/liter) for:
EUCAST breakpoint (mg/
liter) for:
S I R S I R
Enterobacterales 16/4 32/4–64/4 128/4 8/4 16/4 16/4
P. aeruginosa 16/4 32/4–64/4 128/4 16/4 NA 16/4
A. baumannii complex 16/4 32/4–64/4 128/4 IE IE IE
aAbbreviations: S, susceptible; I, intermediate; R, resistant; NA, not applicable; IE, insufficient evidence that
the organism group is a good target with the agent. Values given before and after a slash are for
piperacillin and tazobactam, respectively.
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faecalis ATCC 29212 (BMD only), and Staphylococcus aureus ATCC 29213 (BMD only). Each site tested each
quality control strain a minimum of 20 times.
Data analysis. Results for all isolates tested for P/T susceptibility using the Etest and BMD methods
were included in the analysis. Essential agreement (EA) was defined as agreement between the two
methods 1 doubling dilution. Categorical agreement (CA) between the Etest and BMD methods, as well
as VME, ME, and minor error evaluations, was determined using CLSI or EUCAST breakpoints.
RESULTS
Challenge and clinical studies. A total of 89 isolates, including 67 Enterobacterales,
13 P. aeruginosa, and 9 A. baumannii isolates, were used in the challenge study (the
composition of the challenge set appears in Table S1 in the supplemental material). In
the clinical study, 888 clinical isolates were tested among the 4 sites (242 at HRC, 263
at Rochester, 307 at WashU, and 76 at STL). This population included 708 Enterobac-
terales, 106 P. aeruginosa, and 74 A. baumannii complex isolates. The overall distribution
of these clinical isolates by source of infection was as follows: urine, 45.6%; respiratory
tract, 13.3%; blood, 9.5%; wounds, 8.2%; abscesses, 3.9%; body fluid, 2.6%; skin, 2.3%;
swabs, 2.3%; feces, 2.0%; tissue, 1.8%; bone, 1.3%; foot, 0.8%; gastric, 0.8%; and others
(sample types from which 5 isolates each were obtained), 5.6%.
Evaluation of the performance of the P/T Etest included data for 977 isolates from
the challenge and clinical studies combined. The distribution of species, susceptibility
to P/T, and performance determined using EUCAST or CLSI breakpoints are shown in
Tables 2 and 3. The rates of resistance of the isolates to P/T by Etest for Enterobacterales
were 22.6% and 29.2%, according to CLSI and EUCAST breakpoints, respectively.
Among the P. aeruginosa isolates, resistant isolates accounted for 14.3% and 25.2% of
the isolates according to the CLSI and EUCAST breakpoints, respectively. Resistant A.
baumannii complex isolates represented 38.5% of the A. baumannii complex isolates
tested using CLSI criteria.
Performance compared to FDA requirements. Based on FDA requirements
(90.0% EA and CA, 2.0% VMEs, 3.0% MEs, 95.0% reproducibility, results for
95.0% of the QC isolates within the expected range) (12), we evaluated the perfor-
mance of the P/T Etest using CLSI breakpoints (Table 2). For the Enterobacterales, overall
EA and CA were 96.4% (747/775) and 93.0% (721/775), respectively (Fig. 2A). Two VMEs
were observed among the K. pneumoniae clinical isolates; one isolate had an MIC of
16 g/ml by the P/T Etest and an MIC of 128 g/ml by BMD, and one isolate yielded an
MIC of 8 mg/liter by the P/T Etest and an MIC of 256 mg/liter by BMD. These two
isolates were retested for information. For the first isolate, the retest in triplicate
resulted in 3 P/T Etest MIC results at 16 g/ml and 3 BMD MIC results at 32 g/ml,
TABLE 2 Overall performance of the new P/T Etest categorized according to CLSI-FDA breakpointsa
Breakpoint and organism
No. (%) of isolates with the CLSI-FDA breakpoint
for:
No. (%) of isolates with the following CLSI-FDA
performance:
Total S I R EA CA ME VME mE
Enterobacterales 775 (79.3) 550 (70.8) 51 (6.6) 174 (22.6) 747 (96.4) 721 (93.0) 0 2 (1.1) 52 (6.7)
Citrobacter freundii 41 (4.2) 24 (58.5) 5 (12.2) 12 (29.7) 41 (100) 37 (90.2) 0 0 4 (9.8)
Citrobacter koseri 46 (4.7) 35 (76.1) 2 (4.3) 9 (19.6) 46 (100) 45 (97.8) 0 0 1 (2.2)
Enterobacter cloacae 36 (3.7) 22 (61.1) 3 (8.3) 11 (30.6) 36 (100) 34 (94.4) 0 0 2 (5.6)
Escherichia coli 168 (17.2) 137 (81.6) 15 (8.9) 16 (9.5) 161 (95.8) 153 (91.1) 0 0 15 (8.9)
Klebsiella aerogenes 39 (4.0) 29 (74.4) 6 (15.4) 4 (10.3) 39 (100) 35 (89.7) 0 0 4 (10.3)
Klebsiella pneumoniae 190 (19.5) 79 (41.5) 12 (6.3) 99 (52.6) 179 (94.2) 169 (88.9) 0 2 (2.0) 19 (10.0)
Morganella morganii 41 (4.2) 37 (90.2) 0 4 (9.8) 36 (87.8) 40 (97.6) 0 0 1 (2.4)
Proteus mirabilis 41 (4.2) 38 (92.7) 2 (4.9) 1 (2.4) 40 (97.6) 40 (97.6) 0 0 1 (2.4)
Proteus vulgaris 31 (3.2) 100 (100.0) 0 0 29 (93.5) 31 (100) 0 0
Providencia rettgeri 28 (2.9) 22 (78.6) 0 6 (21.4) 27 (96.4) 28 (100) 0 0 0
Providencia stuartii 36 (3.7) 31 (86.1) 1 (2.8) 4 (11.1) 36 (100) 35 (97.2) 0 0 1 (2.8)
Salmonella enterica 31 (3.2) 31 (100) 0 0 31 (100) 31 (100) 0 0
Serratia marcescens 47 (4.8) 34 (72.3) 5 (10.6) 8 (17.0) 46 (97.9) 43 (91.5) 0 0 4 (8.5)
Pseudomonas aeruginosa 119 (12.2) 89 (74.8) 13 (10.9) 17 (14.3) 117 (98.3) 111 (93.3) 0 0 8 (6.7)
Acinetobacter baumannii complex 83 (8.5) 43 (51.8) 8 (9.6) 32 (38.5) 76 (91.6) 74 (89.2) 0 0 9 (10.8)
aS, susceptible; I, intermediate; R, resistant.
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resolving the error. Regarding the second isolate, a total of 4 triplicate retests were
performed because multiple skipped wells invalidated the run several times. Among
these 12 replicates, Etest provided an MIC at 16 g/ml 11 times and an MIC at 32 g/ml
1 time. When interpretable (i.e., 1 skipped well maximum), the MIC ranged from 8 to
256 g/ml. For this second isolate, a reference MIC value could not be confidently
established due to extensive variability of the results of the reference method. How-
ever, as FDA does not allow categorical error resolution, the initial results were kept for
the CLSI-FDA analysis. Nevertheless, the P/T Etest met the criteria for VMEs for both the
Enterobacterales (1.1%, 2/174) and K. pneumoniae (2.0%, 2/99) isolates separately. For
the Enterobacterales, CA was mostly lowered by a 6.7% (52/775) minor error rate.
Among the P. aeruginosa isolates, EA and CA were 98.3% (117/119) and 93.3%
(111/119), respectively, meeting the criteria for both (Fig. 2B). Using A. baumannii
complex isolates, the P/T Etest met the criteria for EA (91.6%, 76/83) but not those for
CA (89.2%, 74/83) (Fig. 2C). Neither VMEs nor MEs were found among the P. aeruginosa
and A. baumannii complex isolates. Categorical agreement was lowered for the P.
aeruginosa and A. baumannii complex isolates by minor error rates that were 6.7%
(8/119) and 10.8% (9/83), respectively.
Performance compared to ISO requirements. ISO 20776-2 standard performance
criteria (90.0% EA and/or CA, 3.0% VMEs or MEs, 95.0% reproducibility, results for
95.0% of the QC isolates within the expected range) were also used to evaluate the
P/T Etest using EUCAST breakpoints (Table 3). One E. coli isolate and one K. pneumoniae
isolate were excluded from the EUCAST-ISO evaluation because of high variability in the
BMD results per the directions for the ISO 20776-2 standard. For the Enterobacterales,
EA and CA were 96.6% (747/773) and 94.8% (733/773), respectively (Fig. 2A). Among the
Enterobacterales, no VMEs (0/224) were found, but 2 MEs (0.4%, 2/525) were observed:
one E. coli isolate had MIC values of 32 g/ml and 4 g/ml by the P/T Etest and BMD,
respectively, and one Morganella morganii isolate had an MIC result of 32 g/ml by the
P/T Etest and an MIC result of 1 g/ml by BMD. For the Enterobacterales, CA was mostly
lowered by a 4.9% (38/773) minor error rate.
For P. aeruginosa, EA and CA were 98.3% (117/119) and 95.8% (114/119), respec-
tively, meeting the ISO criteria. However, for this species, VME and ME rates were,
respectively, 6.9% (2/29) and 3.3% (3/90), both of which are higher than the ISO criteria
(Fig. 2B). These 5 categorical errors originated from isolates with Etest results 1
doubling dilution apart from the BMD results, therefore falling in the criterion for EA.
TABLE 3 Overall performance of the new P/T Etest categorized according to EUCAST breakpointsb
Organism
No. (%) of isolates with the EUCAST breakpoint
for:
No. (%) of isolates with the following EUCAST-ISO
performance:
Total S I R EA CA ME VME mE
Enterobacterales 773a (79.3) 525 (67.7) 24 (3.1) 224 (29.2) 747 (96.6) 733 (94.8) 2 (0.4) 0 38 (4.9)
Citrobacter freundii 41 (4.2) 23 (56.1) 1 (2.4) 17 (41.5) 41 (100) 40 (97.6) 0 0 1 (2.4)
Citrobacter koseri 46 (4.7) 31 (67.4) 4 (8.7) 11 (23.9) 46 (100) 44 (95.7) 0 0 2 (4.3)
Enterobacter cloacae 36 (3.7) 22 (61.1) 0 14 (38.9) 36 (100) 34 (94.4) 0 0 2 (5.6)
Escherichia coli 167 (17.2) 131 (78.6) 5 (2.9) 31 (18.4) 161 (96.4) 158 (94.6) 1 (0.8) 0 8 (4.8)
Klebsiella aerogenes 39 (4.0) 26 (66.7) 3 (7.7) 10 (25.6) 39 (100) 34 (87.2) 0 0 5 (12.8)
Klebsiella pneumoniae 189 (19.5) 72 (37.4) 7 (3.7) 110 (58.9) 179 (94.7) 175 (92.6) 0 0 14 (7.4)
Morganella morganii 41 (4.2) 37 (90.2) 0 4 (9.8) 36 (87.8) 39 (95.1) 1 0 1 (2.4)
Proteus mirabilis 41 (4.2) 37 (90.2) 1 (2.4) 3 (7.3) 40 (97.6) 40 (97.6) 0 0 1 (2.4)
Proteus vulgaris 31 (3.2) 31 (100) 0 0 29 (93.5) 31 (100) 0 0
Providencia rettgeri 28 (2.9) 22 (78.6) 0 6 (21.4) 27 (96.4) 28 (100) 0 0 0
Providencia stuartii 36 (3.7) 30 (83.3) 1 (2.8) 5 (13.9) 36 (100) 33 (91.7) 0 0 3 (8.3)
Salmonella enterica 31 (3.2) 31 (100) 0 0 31 (100) 31 (100) 0 0
Serratia marcescens 47 (4.8) 32 (68.1) 2 (4.3) 13 (27.7) 46 (97.9) 46 (97.9) 0 0 1 (2.1)
Pseudomonas aeruginosa 119 (12.2) 90 (74.8) 29 (25.2) 119 (98.3) 114 (95.8) 3 (3.3) 2 (6.9) 0
Acinetobacter baumannii complex 83 (8.5) 76 (91.6) NA NA NA NA
aOne E. coli isolate and one K. pneumoniae isolate were excluded from the EUCAST-ISO evaluation because of high variability in BMD results per ISO 20776-2 standard
directions.
bS, susceptible; I, intermediate; R, resistant; NA, not applicable.
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FIG 2 Frequency tables for Enterobacterales (A), P. aeruginosa (B), and A. baumannii (C) categorized according
to CLSI-FDA and EUCAST breakpoints. Blue lines, EUCAST breakpoint; red lines, CLSI breakpoint; green lines,
EUCAST and CLSI breakpoints. a, CLSI/EUCAST interpretive criteria; b, two isolates excluded from the
evaluation according to ISO criteria because the variability was too high; c, changes in BMD values due to ISO
resolution of MEs and VMEs.
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Reproducibility study. The reproducibility study included 4 P. aeruginosa isolates,
3 E. coli isolates, 2 K. pneumoniae isolates, 1 M. morganii isolate, and 2 A. baumannii
isolates. Evaluation in triplicate for 3 days resulted in 108 determinations per site and
324 in total. All determinations fell within 1 doubling dilution of the mode, so
reproducibility met the criteria for best- and worst-case calculations and was 100% for
both between-site (270/270) and within-site (90/90) reproducibility, according to both
FDA and ISO requirements (Table 4).
Quality control. A total of 85 QC replicates were performed among the 4 sites. One
hundred percent of the results were within the expected ranges defined by the CLSI
M100 (13) and EUCAST (14) standards for both the Etest and BMD, meeting both FDA
and ISO requirements.
DISCUSSION
P/T is a widely used -lactam–-lactamase inhibitor combination for treating several
complicated infections, as recognized in different treatment guidelines. Recently, a
renewed interest in the use of this combination against ESBL producers has emerged,
particularly to avoid the use of carbapenems in order to limit the spread of
carbapenemase-producing bacteria (4–6, 17).
On the other hand, routine clinical laboratories also use other methods as alterna-
tives to the standard BMD to obtain MIC values. These methods need to be easy to
perform and must be properly evaluated according to performance standards (18). One
of these methods is diffusion with gradient strips, which also included P/T strips.
However, bioMérieux, one of the manufacturers of the gradient test, decided to
discontinue production of the Etest strip for P/T (formerly called Etest PTc) concomi-
tantly with a communication from the EUCAST Development Laboratory alerting about
the inaccuracy of the susceptibility testing results obtained with these strips (http://
www.eucast.org/ast_of_bacteria/warnings/). Moreover, in the MERINO trial, some of the
MIC values were obtained with the withdrawn Etest PTc strip, and the results were used
to establish correlations with clinical outcomes (17). This fact created controversies due
to potential interpretive errors (a high VME rate), and further analyses of the isolates
involved in this trial using BMD have been performed (19).
After the EUCAST warning, the piperacillin-tazobactam strip was redeveloped
and evaluated in the large multicenter trial summarized in this paper. Results from
this evaluation were used for the CE (December 2018) and FDA (January 2019)
approvals. To the best of our knowledge, this is the first study comparing the
performance for this new P/T Etest strip to that of the standard BMD. Similar evalua-
tions have recently been performed for ceftolozane-tazobactam and ceftazidime-
avibactam MIC strips (20, 21).
TABLE 4 Reproducibility of the new P/T Etest
Organism
No. of isolates with the following no. of dilutions
different from test mode
MIC (mg/liter)
by test modeOff scale 2 1 0 1 2 Off scale
A. baumannii 12 15 32
A. baumannii 27 16
E. coli 15 12 32
E. coli 7 20 32
E. coli 5 22 16
K. pneumoniae 27 2
K. pneumoniae 9 17 1 2
M. morganii 13 14 16
P. aeruginosa 6 18 3 128
P. aeruginosa 19 8 16
P. aeruginosa 23 4 16
P. aeruginosa 22 5 2
Total 0 0 52 239 33 0 0
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In our study, we obtained a good overall performance with this new P/T Etest, with
EA values being higher than 90% for Enterobacterales, P. aeruginosa, and A. baumannii
complex isolates, exhibiting an excellent correlation between Etest and BMD according
to both EUCAST-ISO and CLSI-FDA recommendations. Two VMEs corresponding to two
clinical K. pneumoniae isolates were observed in the evaluation performed according to
FDA recommendations. Only one of those two VMEs was reproduced when the isolates
were retested. Indeed, for the second isolate, BMD highlighted a variability too large to
conclude its resistance to piperacillin-tazobactam with confidence.
In the evaluation performed according to EUCAST-ISO recommendations, 3 (3.3%)
MEs and 2 (6.9%) VMEs were observed among the P. aeruginosa isolates, resulting in the
lack of achievement of the ME/VME rates for this microorganism. However, these results
need to be analyzed by consideration of the lack of an intermediate category for P/T
with P. aeruginosa. As a consequence, when the reference result is just on the
breakpoint MIC value, 1 dilution apart from the Etest result, either a ME or a VME is
produced. Indeed, the 5 categorical errors originated from isolates with Etest-based MIC
results 1 doubling dilution apart from the BMD results, which were, consequently, in the
EA category.
The strengths of this study include the use of a collection of isolates with different
mechanisms of resistance to different -lactam antibiotics (see Table S1 in the supple-
mental material), the large number of clinical isolates obtained, a multicenter evalua-
tion comprising three tertiary care medical centers in different geographic areas, and
the use of BMD as a reference method with a standardized and validated preparation
of panels. The limitations include the lack or a limited number of resistant isolates of
specific species. Indeed, no resistant Proteus mirabilis, Proteus vulgaris, or Salmonella
enterica isolates were found when performing the trial. Despite these limitations, the
results of this trial resulted in both the CE marking and the FDA clearance of the P/T
Etest. In addition, using the P/T Etest, the EUCAST Development Laboratory generated
data leading to the lifting of the warning on the piperacillin-tazobactam Etest that had
been issued in 2015.
In conclusion, compared to the results of the reference BMD method, the results of
this multicenter trial support the accuracy of the new P/T Etest for determining the
MICs for Enterobacterales, P. aeruginosa, and A. baumannii complex isolates in the
clinical setting.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.
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